Key Highlights
- Oragenics (NYSE American: OGEN) activated its Phase 2a feasibility trial for ONP-002 at three Australian sites.
- ONP-002 is being studied for moderate-to-severe concussion in the acute through subacute phases.
- The company plans to submit an Investigational New Drug application to the FDA in the fourth quarter of 2026.
- Oragenics (NYSE American: OGEN) shares traded at $0.50, roughly flat on the day.
Third Site Activated in Australia
Oragenics (NYSE American: OGEN) said its Phase 2a feasibility trial for ONP-002 has achieved full activation across three sites in Australia. ONP-002 is being developed for moderate-to-severe concussion in the acute through subacute phases, an area with limited approved treatment options.
FDA Pathway Advancing in Parallel
The Australian program builds on earlier progress, including the enrollment of the trial's first patient and a Type B meeting request submitted to the FDA to advance the U.S. regulatory pathway for ONP-002. Oragenics (NYSE American: OGEN) has said it plans to submit an Investigational New Drug application to the FDA in the fourth quarter of 2026, with a second Australian site having been activated earlier in the year.
Shares Little Changed
Oragenics (NYSE American: OGEN) shares traded at $0.50, essentially unchanged on the day, giving the company a market Capitalization of $2.26 million as it continues to build out its concussion trial infrastructure across Australia ahead of a planned U.S. filing.
What is ONP-002 being developed for?
Moderate-to-severe concussion in the acute through subacute phases.
How many Australian sites are now active?
Three sites have been activated for the Phase 2a feasibility trial.
What is the next regulatory step?
Oragenics plans to submit an IND application to the FDA in the fourth quarter of 2026.






Please wait processing your request...